New study underscores FluMist safety
A new study in the Journal of the American Medical Association confirms that FluMist has proved safe among healthy people from the ages of 5 to 49. FluMist is a live, attenuated influenza vaccine administered as a nasal spray. Though it was approved two years ago, it has made only slow gains in the market--even during the flu vaccine shortage last year. But researchers now have 2.5 million instances where people have taken FluMist, allowing the new safety study to look for possible problems.
- read this report from HealthDay News for more information
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
